開示 全文検索
EDINETやTDnetで開示されたＩＲ情報から全文検索することができます。
「 2 」の検索結果
対象開示が多い為、表示を制限しています。
ページ数： 500 ページ
| 発表日 | 時刻 | コード | 企業名 |
|---|---|---|---|
| 02/14 | 12:00 | 7240 | ＮＯＫ |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| statements Note to applying of specific accounting of the consolidated quarterly financial statements true Dec 2021 ( 注 ) 詳細は、添付資 料 P.8「2. 四半 期連結財務諸表及び 主な注記 (3) 四半 期連結財務諸表に関 する注記事項 ( 四半 期連結財務諸表の作 成に特有の会計処理 の適用 )」をご覧く ださい。。 Notes, Quarterly-Changes in accounting policies and accounting estimates | |||
| 02/14 | 12:00 | 7494 | コナカ |
| Summary of Financial Results for the first quarter 2022 その他 | |||
| estimates and retrospective restatement true Dec 2021 - ( 注 ) 詳細は、添付資 料 P7「2. 四半期連 結財務諸表及び主な 注記 (3) 四半期連結 財務諸表に関する注 記事項 ( 会計方針の 変更 )」をご覧くだ さい。 Notes, Quarterly-Number of issued and outstanding shares common stock Number of issued and outstanding shares (common stock) Number of issued and outstanding | |||
| 02/14 | 12:00 | 7480 | スズデン |
| [Delayed]Consolidated Financial Results for the Nine Months Ended December 31, 2021 [Japanese GAAP] その他 | |||
| , etc. is not provided. (2) Consolidated Financial Position Total assets Net assets Equity ratio Net assets per share Million yen Million yen % Yen As of December 31, 2021 30,046 16,855 56.1 1,207.37 As of March 31, 2021 26,441 16,396 62.0 1,175.22 (Reference) Equity: As of December 31, 2021: ¥16,855 | |||
| 02/14 | 12:00 | 7593 | ＶＴホールディングス |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| forecast from the most recent dividend forecast Correction of dividend forecast from the most recent dividend forecast Note to dividends Annual - Note to dividends Annual 2022 年 3 月期第 2 四半期末配当金の 内訳普通配当 10 円 00 銭特別配当 1 円 00 銭 2022 年 3 月 期 ( 予想 ) 期末配当 金の内訳普通配当 10 円 00 銭特別配当 1 円 00 銭 Quarterly Forecasts | |||
| 02/14 | 12:00 | 7780 | メニコン |
| Consolidated Financial Results for the Nine Months Ended December 31, 2021 その他 | |||
| 887 +332 +59.8% Asia *2 4,129 8,614 +4,484 +108.6% Oceania and Africa, etc. 305 381 +75 +24.6% (2) Healthcare and life care 1,250 4,760 +3,510 +280.8% Net sales in Japan 1,216 2,267 +1,051 +86.4% Overseas sales 33 2,492 +2,458 +7288.0% *1 “Product sales” refers to contact lenses and lens care | |||
| 02/14 | 12:00 | 7780 | メニコン |
| Consolidated Financial Results for the Nine Months Ended December 31, 2021 [Japanese GAAP] その他 | |||
| issued March 31, 2020), etc. has been applied from the beginning of the first quarter of the current fiscal year. The figures for the Nine Months Ended December 31, 2021 are after the application of the said accounting standards. 2. Effective October 1, 2021, we conducted a 2-for-1 stock split of | |||
| 02/14 | 12:00 | 7780 | メニコン |
| Notice of Revision to Financial Forecast その他 | |||
| change (%) 0.2 6.7 8.0 5.3 ― (Reference) Results of the previous year (Fiscal year ending 86,209 8,106 8,348 5,952 JPY 78.84 March 31, 2021) ※Effective October 1, 2021, we conducted a 2-for-1 stock split of common stock. Accordingly, the basic earnings per share are calculated on the assumption | |||
| 02/14 | 12:00 | 7999 | ＭＵＴＯＨホールディングス |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| Note to dividends Note to dividends Annual true 2022 年 3 月期期末配 当金 35 円 00 銭は、普 通配当 30 円 00 銭と創 立 70 周年記念配当 5 円 00 銭の合計額です。 配当予想の修正につ いては、本日 (2022 年 2 月 14 日 ) 公表い たしました「 通期業 績予想の修正並びに 配当予想 ( 増配 )に 関するお知らせ」を ご覧ください。 Quarterly Forecasts Quarterly forecasts Quarterly forecasts Title for forecasts Preamble | |||
| 02/14 | 12:00 | 6254 | 野村マイクロ・サイエンス |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| dividend forecast Correction of dividend forecast from the most recent dividend forecast Annual Note to dividends Note to dividends Annual true 配当予想の修正の詳 細につきましては、本 日 (2022 年 2 月 14 日 ) 公表いたしまし た「 期末配当予想の 修正に関するお知ら せ」をご覧ください。 Quarterly Forecasts Quarterly forecasts Quarterly forecasts Title for | |||
| 02/14 | 12:00 | 8072 | 日本出版貿易 |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| share (Yen) 264.56 23.16 Diluted earnings per share (Yen) - - Note to consolidated operating results Note to operating results ( 注 1)2022 年 3 月期第 3 四半期の親会社株 主に帰属する四半期 純利益の対前年同四 半期増減率は1,000% を超えるため「―」 と記載しております。 ( 注 2)「 収益認識に 関する会計基準 」 ( 企業会計基準第 29 号 2020 年 3 月 31 日 ) 等を第 1 四半期連結 会計期間の期首から 適用しており | |||
| 02/14 | 12:00 | 8746 | 第一商品 |
| Summary of Financial Results for the third quarter 2022 その他 | |||
| true true Dec 2021 - ( 注 ) 詳細は、添付資料 P.8「2. 四半期連 結財務諸表及び主な 注記 (3) 四半期連 結財務諸表に関する 注記事項 ( 会計上の 見積りの変更 )」を ご覧ください。 Notes, Quarterly-Number of issued and outstanding shares common stock Number of issued and outstanding shares (common stock) Number of issued and outstanding shares (common stock) Others | |||
| 02/14 | 12:00 | 3900 | クラウドワークス |
| FY2022 1Q Presentation Material for IR その他 | |||
| -term, CrowdWorks aims to reach “$18.2 billion in work distribution GMV." This means a platform that pays to more than 360,000 people based on Japan’s average annualized income. We will build Japan's largest online employment infrastructure with more than FY20XX GMV $18.2 billion (2 trillion yen | |||
| 02/14 | 12:00 | 3900 | クラウドワークス |
| Notice of Revision (Upward Revision) of Consolidated Financial Forecast for the Fiscal Year Ending September 30, 2022 その他 | |||
| - - - Change (B-A) Rate of changes (%) 736 ~1,139 7.9 ~12.9% 50 - - - 7.1% - - - 2.Reason for Revision of Financial Forecasts As stated in the "Notice of Release of Consolidated Financial Forecast in Accordance with Transition to Consolidated Financial Statements" released on November 15, 2021, we | |||
| 02/14 | 12:00 | 3900 | クラウドワークス |
| Summary of Financial Results for the First Quarter of the Fiscal Year Ending September 30, 2022 [Japan Standards] (Consolidated) その他 | |||
| (171.7%) Q1 FY ended September 30, 2021: 78 million yen (-%) Profit per share Diluted profit per share Yen Yen Q1 FY ending Sep. 30, 2022 14.09 13.86 Q1 FY ended Sep. 30, 2021 6.00 5.89 (2) Consolidated Financial Position Total assets Net assets Capital adequacy ratio Million yen Million yen % As | |||
| 02/14 | 12:00 | 4478 | フリー |
| Announcement Regarding Issuance of New Restricted Shares to freee Employees その他 | |||
| Issuance”) as follows. 1. Overview of the Share Issuance (1) Pay-in date March 18, 2022 (2) Type and number of shares to 45,311 common shares of the Company be issued (3) Issue price of shares JPY 4,385 per share (4) Total issue price JPY 198,688,735 (5) Allottees 45,311 shares to be allocated to 154 | |||
| 02/14 | 12:00 | 4478 | フリー |
| Financial Results for Q2 FY2022.6 その他 | |||
| [–%] Six months ended December 31, 2020: ¥(716) million [–%] 2. Adjusted operating profit is the sum of the operating profit, stock-based compensation expenses, expenses for amortization of acquisition-related intangible assets, and one-time cost. Basic earnings per share Diluted earnings per share Six | |||
| 02/14 | 12:00 | 3913 | ｓＭｅｄｉｏ |
| Summary of Financial Results 2021 その他 | |||
| activities 2 1 Cash and equivalents, end of period 570 806 Note to consolidated cash flows Note to cash flows -Business Results-Note to business results Dec 2021 Note to business results Note to business results Note to consolidated financial results Note to consolidated financial results - Dividends (in | |||
| 02/14 | 12:00 | 4583 | カイオム・バイオサイエンス |
| Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021 その他 | |||
| incurred a loss for each respective period. (2) Financial Position Total Assets Net Assets Equity Ratio Net Assets per Share Million yen Million yen % Yen As of Dec. 31, 2021 2,339 1,893 79.4 45.55 As of Dec. 31, 2020 3,494 3,109 88.2 77.99 (Reference) Equity As of Dec. 31, 2021: 1,857 million yen As of | |||
| 02/14 | 12:00 | 4583 | カイオム・バイオサイエンス |
| Supplementary Information for Financial Results FY12/21 その他 | |||
| Supplementary Information for Financial Results FY12/21 Feb. 14, 2022 To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs Chiome Bioscience Inc.Agenda 1.Overview of FY12/21 “Financial results” 2.Overview of FY12/21 “Operation highlights | |||
| 02/14 | 12:00 | 4591 | リボミック |
| Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31, 2021 (Based on Japanese GAAP) その他 | |||
| December 31, 2021 (39.86) – Nine months ended December 31, 2020 (34.14) – Notes:1.RIBOMIC Inc. (hereinafter “the Company”) has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020), etc. effective from the beginning of the first quarter ended June 30, 2021. 2 | |||